

Clinical trials of out of hospital Enoxaparin

TrialResults-center www.trialresultscenter.org

1 thrombosis prevention

| Trial | Treatments | Patients | Trials design and methods |
|---|--|------------|---------------------------|
| out of hospital Enoxaparin vs standard prophylaxis | | | |
| Bergqvist , 1996 n=117/116 | 65279;in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 30 days versus 65279;Enoxaparin 40 mg once a day for 10-11 days | 65279;THR | |
| Planes , 1996 n=90/89 | 65279;in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 35 days versus Enoxaparin 40 mg once a day for 13-15 days | THR | |
| Comp , 2001 n=441/432 | 65279;in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 27-29 days versus Enoxaparin 30 mg twice a day for 7-10 days | THR or TKR | |

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>

References

Bergqvist, 1996:

Bergqvist D, Benoni G, Bjrgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700 [8703168]

Planes, 1996:

Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. *Lancet* 1996;348:224-8 [[8684199](#)]

Comp, 2001:

Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, Landon GC, Jov M Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. *J Bone Joint Surg Am* 2001;83-A:336-45 [[11263636](#)]

Entry terms: enoxaparin, Lovenox, Clexane